These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 29487338)

  • 1. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
    Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
    Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
    Li LX; Fan LX; Zhou JX; Grantham JJ; Calvet JP; Sage J; Li X
    J Clin Invest; 2017 Jun; 127(7):2751-2764. PubMed ID: 28604386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
    Liu L; Liu F; Guan Y; Zou J; Zhang C; Xiong C; Zhao TC; Bayliss G; Li X; Zhuang S
    FASEB J; 2021 Jul; 35(7):e21715. PubMed ID: 34143514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.
    Xu G; Liu G; Xiong S; Liu H; Chen X; Zheng B
    J Biol Chem; 2015 Feb; 290(9):5414-23. PubMed ID: 25583990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
    Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
    Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activity.
    Gao L; Chen S; Hong M; Zhou W; Wang B; Qiu J; Xia J; Zhao P; Fu L; Wang J; Dai Y; Xie N; Yang Q; Huang HD; Gao X; Zou C
    Signal Transduct Target Ther; 2021 Jul; 6(1):250. PubMed ID: 34219129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonizing binding of cell cycle and apoptosis regulatory protein 1 (CARP-1) to the NEMO/IKKγ protein enhances the anticancer effect of chemotherapy.
    Venkatesh J; Sekhar SC; Cheriyan VT; Muthu M; Meister P; Levi E; Dzinic S; Gauld JW; Polin LA; Rishi AK
    J Biol Chem; 2020 Mar; 295(11):3532-3552. PubMed ID: 32024692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.
    Gao S; Wang Z; Wang W; Hu X; Chen P; Li J; Feng X; Wong J; Du JX
    J Biol Chem; 2017 Jul; 292(30):12702-12712. PubMed ID: 28588028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of substrate methylation and inhibition of SMYD2.
    Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
    Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
    Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
    Wu L; Kou F; Ji Z; Li B; Zhang B; Guo Y; Yang L
    Cell Death Dis; 2021 May; 12(5):439. PubMed ID: 33935284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.